About Benjamin C. Creelan
Board Certified in Medical Oncology
Excellence in Research
Works for Specialty Center
Creelan plays a key role in the Thoracic Oncology Program at Moffitt Cancer Center that has been lauded for its innovative approach, mixing cutting-edge discoveries with old-fashioned personalization of care.
“I think a patient’s best chance at beating their cancer is with the Moffitt Cancer Center,” he said confidently.
Creelan has focused on emerging immunotherapies that already are working for various thoracic malignancies.
He is involved in several clinical trials, allowing patients to benefit from the latest advances that are working their way through the Food and Drug Administration approval process.
“Lung cancer, for example, has had so many advancements in recent years. It’s become a much more complicated field,” he said. “Traditionally, we always treated lung cancer by targeting the cancer cells. Now we are targeting the patient’s own immune system. And every patient has an immune system that is capable of killing cancer cells.”
Leading Immunotherapy Research
Creelan is running a much-anticipated clinical trial with Opdivo (nivolumab) for patients with advanced or solid tumors.
Opdivo already has shown great success with several cancers, including lung cancer.
One of the studies aimed at mesothelioma patients involves the immunotherapy combination of Opdivo and Cyramza (ramucirumab), which has the potential to replace chemotherapy and avoid many of the complications that often accompany it.
“My goal is to use clinical trials to activate the immune system to fight the cancer,” he said.
He also is working on a phase II clinical trial testing transarterial chemoperfusion for unresectable pleural mesothelioma.
The procedure involves identifying specific blood vessels that feed mesothelioma tumors, then sending higher-than-normal doses of chemotherapy to slow or stop their growth.
Another clinical trial is studying a chemotherapy combination designed specifically for mesothelioma patients with low expression of the enzyme argininosuccinate synthetase 1.
Career Stops in Maryland, Pennsylvania and Florida
Creelan graduated from the Jefferson Medical College in Maryland.
He did his residency in internal medicine at Thomas Jefferson University in Philadelphia.
Creelan completed a hematology oncology fellowship at the University of South Florida before accepting a position at Moffitt.
He received a master’s degree in clinical and translational research through a sponsorship from the National Institutes of Health.
Disclaimer: Dr. Benjamin C. Creelan has no professional affiliation with Asbestos.com.
1 Cited Article Sources
- Moffitt Cancer Center. (n.d.). Benjamin C. Creelan, MD. Retrieved from: https://moffitt.org/providers/benjamin-creelan/
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified April 8, 2019